(Q39591635)

13 September 2017

title

Inactivated hepatitis A vaccine: long-term antibody persistence (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

2

Kundi M

1 reference

13 September 2017

Wiedermann G

1

1 reference

13 September 2017

Ambrosch F

3

1 reference

13 September 2017

Safary A

4

1 reference

13 September 2017

D'Hondt E

5

1 reference

13 September 2017

Delem A

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

13 September 2017

number of pages

4

1 reference

inferred from page(s)

published in

Vaccine

1 reference

13 September 2017

volume

15

1 reference

13 September 2017

issue

6-7

1 reference

13 September 2017

page(s)

612-615

1 reference

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Preparation and immunogenicity of an inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Persistence of vaccine-induced antibody to hepatitis A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Vaccination against hepatitis A: control 3 years after the first vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Protection against hepatitis A by an inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

Hepatitis B vaccination: how long does protection last?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900242-3

7 January 2021

10.1016/S0264-410X(96)00242-3

Identifiers

DOI

1 reference

release_5oqbqlxcbveh5fqxh5nqw433su

13 September 2017

Fatcat ID

0 references

1 reference